Prediction: Eli Lilly Stock Could Reach $1,200 by 2026

Analysts at Motley Fool have predicted that Eli Lilly (LLY) could reach $1,200 by 2026, primarily driven by robust international growth. This forecast comes amid the company's strong performance in the pharmaceutical sector, especially in diabetes and obesity treatments.

Forecast Details

The new prediction from Motley Fool analysts highlights that expansion into international markets, particularly Asia and Europe, will significantly boost the company's revenues. The stock currently trades around $900, implying a potential upside of over 30%.

Analyst Rationale

The analysts base their forecast on several factors:

• International Growth: Lilly's expansion into emerging markets like China and India.
• Strong Pipeline: Drugs like Mounjaro and Zepbound achieving record sales.
• Innovation: Heavy investments in R&D.

Context

Eli Lilly has been one of the best-performing healthcare stocks over the past two years, rising over 50% since the start of 2025. However, risks remain, including fierce competition from Novo Nordisk and regulatory challenges.

What to Make of It

The forecast is optimistic but not guaranteed. Investors should consider potential risks such as changes in drug policies and competition. Further research is recommended before making any investment decisions.